ArticleCytotechnology2025
Sevoflurane induces Ca
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sevoflurane, a widely utilized inhalational anesthetic, has been shown in previous studies to inhibit the proliferation and invasion of non-small cell lung cancer (NSCLC) cells. However, whether sevoflurane affects the metastasis of small cell lung cancer (SCLC) cells remains unexplored. This study's primary objective was to investigate the mechanism by which sevoflurane induces calcium overload and EFHD1 upregulation, thereby contributing to pyroptosis in SCLC cells. NCI-H446 cells were treated with sevoflurane at concentrations of 0%, 0.6%, 3% and 15%. Cell proliferation was assessed using the CCK8 assay, while cell migration and invasion were analyzed using the Transwell assay. EFHD1 expression was determined by q-PCR and Western blot. Calcium content, ROS levels, and CCO content were measured using respective assay kits, and mitochondrial morphology was observed using transmission electron microscopy. Western blotting was performed to detect the expression of caspase-1 and GSDMD. All procedures were repeated under conditions of EFHD1 overexpression or silencing. Sevoflurane inhibited the proliferation, migration, and invasion of NCI-H446 cells, concurrently exerting a significant pro-pyroptotic effect. This was mediated by mitochondrial calcium overload, EFHD1 upregulation, and subsequent mitochondrial damage-induced pyroptosis. Sevoflurane significantly enhances pyroptosis in NCI-H446 cells, thereby potentially reducing cancer cell dissemination during surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.